Australia’s Groundbreaking Stem Cell Sciences Closed By New U.S. Owner
This article was originally published in PharmAsia News
Executive SummaryStem Cell Sciences, Australia's first stem-cell biotech, is going out of business, the result of a decision by its new U.S. owner. StemCells of California acquired the intellectual property of SCS for handling embryonic stem cells and other technology along with patents on 20 sets of products. The closing of SCS leaves Australia with only Mesoblast, since Bresagen ended its stem-cell work and Embryonic Stemcells relocated to Singapore. The California company bought SCS in March for $4 million. (Click here for more
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.